RECKITT BENCKIS/S (OTCMKTS:RBGLY) has been given an average rating of “Hold” by the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have assigned a buy recommendation to the company.
A number of brokerages have recently weighed in on RBGLY. Deutsche Bank reaffirmed a “buy” rating on shares of RECKITT BENCKIS/S in a research report on Tuesday, April 3rd. Zacks Investment Research lowered RECKITT BENCKIS/S from a “hold” rating to a “sell” rating in a research report on Wednesday, March 14th. Credit Suisse Group reaffirmed a “neutral” rating on shares of RECKITT BENCKIS/S in a research report on Tuesday, February 20th. Finally, Societe Generale raised RECKITT BENCKIS/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 22nd.
Shares of RECKITT BENCKIS/S traded up $0.29, reaching $16.41, during trading on Friday, Marketbeat Ratings reports. 673,769 shares of the stock were exchanged, compared to its average volume of 952,503. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.85. RECKITT BENCKIS/S has a 1-year low of $15.14 and a 1-year high of $21.79. The firm has a market capitalization of $55.75 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 4.05 and a beta of 0.97.
About RECKITT BENCKIS/S
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.